Plasbumin-20 Market Report 2026

Plasbumin-20 Market Overview

• The Plasbumin-20 market growth in the historic period has been driven by use of albumin in volume replacement, growth in surgical procedures • Market expansion is supported by rising geriatric population, increase in critical care admissions • Growth Driver: Rising Chronic Diseases Drive Growth In The Plasbumin-20 Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Plasbumin-20 Market?

Plasbumin-20 is a human albumin solution derived from pooled human plasma, used primarily to restore and maintain blood volume and protein levels in patients experiencing conditions such as hypovolemic shock, hypoproteinemia, and certain liver disorders. It is commonly used in clinical settings to support patients undergoing surgeries, managing acute liver failure, or treating other medical conditions that result in low blood protein levels. The main product types in plasbumin-20 are human albumin and recombinant albumin, which are used to manage a variety of medical conditions. Human albumin is a protein derived from pooled human plasma that helps maintain blood volume and pressure and is used to treat conditions involving low protein levels and fluid imbalance. The primary indications for Plasbumin-20 include hypovolemic shock, hypoproteinemia, ARDS, cardiopulmonary bypass, and acute liver failure. It is distributed through channels such as direct sales, pharmaceutical distributors, and online sales. The users of Plasbumin-20 consist of both adult and geriatric patients.

What Is The Plasbumin-20 Market Growth Forecast?

The growth in the forecast period can be attributed to rising geriatric population, increase in critical care admissions, expansion of recombinant albumin development, improved plasma collection infrastructure, growth of hospital based treatments. Major trends in the forecast period include rising demand for plasma derived therapies, growth of albumin use in critical care, expansion of surgical and trauma applications, increased focus on protein replacement therapy, improved plasma fractionation techniques.

What Are The Drivers Of The Plasbumin-20 Market?

The increase in chronic diseases is expected to propel the growth of the plasbumin-20 market going forward. Chronic diseases are long-lasting health conditions, such as heart disease, diabetes, and arthritis, that persist for a year or more and require ongoing medical attention or limit daily activities. The rise in chronic diseases is largely attributed to factors such as an aging population, lifestyle changes, urbanization, and genetic predispositions. As the global incidence of chronic diseases continues to rise, especially with aging populations and lifestyle-related factors, the demand for supportive therapies such as Plasbumin-20 is set to increase, making it an important element in managing long-term healthcare challenges. For instance, in May 2025, according to the Centers for Disease Control and Prevention, a US-based government public health agency, chronic obstructive pulmonary disease (COPD) was reported as the fifth leading cause of death in the United States in 2023, resulting in 141,733 deaths. In the same year, the age-adjusted prevalence of diagnosed COPD in adults aged 18 years and older was 3.8 percent. Therefore, the increase in chronic diseases drives the growth of the plasbumin-20 industry. The global expansion of healthcare infrastructure is expected to propel the growth of the plasbumin-20 going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems that are necessary for delivering healthcare services to a population. The global expansion of healthcare infrastructure is driven by several key factors, including the aging global population, the increase in chronic diseases, and technological advancements. Plasbumin-20 is a pharmaceutical product used primarily for plasma protein therapy. It is a human albumin solution that is derived from pooled human plasma and is typically used in various medical conditions to improve clinical outcomes. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year, when there were 6,093 hospitals. Therefore, the global expansion of healthcare infrastructure is driving the growth of the plasbumin-20 industry. The rising aging population is expected to drive the plasbumin-20 market going forward. The aging population consists of individuals aged 65 and older, a trend driven by increased life expectancy and declining birth rates. This demographic shift is fueled by advancements in healthcare, medical technology, and enhanced living conditions. Plasbumin-20 is vital for the aging population as it aids in managing conditions associated with low protein levels, supporting better health outcomes, and enhancing the body's resilience against age-related medical challenges, such as weakened immune function and recovery from surgeries or trauma, ultimately promoting improved quality of life and independence in older adults. For instance, in January 2024, according to the statistics published by the Population Reference Bureau (PRB), a US-based nonprofit organization, it is anticipated that the number of Americans 65 and older will climb from 58 million in 2022 to 82 million in 2050 (a 47% increase) and that their proportion of the overall population will increase from 17% to 23%. Therefore, the rising aging population is driving the plasbumin-20 industry.

Key Players In The Global Plasbumin-20 Market

Major companies operating in the plasbumin-20 market are Grifols SA

What Defines the Plasbumin-20 Market?

The Plasbumin-20 market consists of sales of Plasbumin 20% injection (100 mL) and Plasbumin 20% infusion (50 mL). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Plasbumin-20 Market Report 2026?

The plasbumin-20 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-20 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.